- Home
- JKHY vs EXEL Comparison
JKHY vs EXEL Comparison
Compare JKHY & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JKHY
- EXEL
- Stock Information
- Founded
- JKHY 1976
- EXEL 1994
- Country
- JKHY United States
- EXEL United States
- Employees
- JKHY N/A
- EXEL N/A
- Industry
- JKHY Retail: Computer Software & Peripheral Equipment
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JKHY Technology
- EXEL Health Care
- Exchange
- JKHY Nasdaq
- EXEL Nasdaq
- Market Cap
- JKHY 12.1B
- EXEL 9.8B
- IPO Year
- JKHY N/A
- EXEL 2000
- Fundamental
- Price
- JKHY $181.17
- EXEL $43.04
- Analyst Decision
- JKHY Hold
- EXEL Buy
- Analyst Count
- JKHY 9
- EXEL 18
- Target Price
- JKHY $184.22
- EXEL $38.76
- AVG Volume (30 Days)
- JKHY 756.7K
- EXEL 3.9M
- Earning Date
- JKHY 05-06-2025
- EXEL 05-13-2025
- Dividend Yield
- JKHY 1.28%
- EXEL N/A
- EPS Growth
- JKHY 13.10
- EXEL 237.58
- EPS
- JKHY 5.87
- EXEL 2.20
- Revenue
- JKHY $2,319,828,000.00
- EXEL $2,298,922,000.00
- Revenue This Year
- JKHY $8.37
- EXEL $10.39
- Revenue Next Year
- JKHY $6.75
- EXEL $10.74
- P/E Ratio
- JKHY $30.86
- EXEL $19.53
- Revenue Growth
- JKHY 5.92
- EXEL 24.49
- 52 Week Low
- JKHY $157.00
- EXEL $20.40
- 52 Week High
- JKHY $196.00
- EXEL $48.85
- Technical
- Relative Strength Index (RSI)
- JKHY 53.98
- EXEL 59.93
- Support Level
- JKHY $177.88
- EXEL $42.21
- Resistance Level
- JKHY $185.19
- EXEL $43.75
- Average True Range (ATR)
- JKHY 2.94
- EXEL 1.60
- MACD
- JKHY -0.14
- EXEL -0.09
- Stochastic Oscillator
- JKHY 47.08
- EXEL 53.96
About JKHY Jack Henry & Associates Inc.
Jack Henry is a leading provider of core processing and complementary services, such as electronic funds transfer, payment processing, and loan processing for us banks and credit unions, with a focus on small and midsize banks. Jack Henry serves almost 1,000 banks and over 700 credit unions.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.